[1]
|
Carbone, A., Borok, M., Damania, B., et al. (2021) Castleman Disease. Nature Reviews Disease Primers, 7, Article No. 84. https://doi.org/10.1038/s41572-021-00317-7
|
[2]
|
Simpson, D. (2018) Epidemiology of Castleman Disease. Hematology/Oncology Clinics of North America, 32, 1-10.
https://doi.org/10.1016/j.hoc.2017.09.001
|
[3]
|
Liu, A.Y., Nabel, C.S., Finkelman, B.S., et al. (2016) Idiopathic Multicentric Castleman’s Disease: A Systematic Literature Review. The Lancet Haematology, 3, E163-E175. https://doi.org/10.1016/S2352-3026(16)00006-5
|
[4]
|
Parez, N., Bader-Meunier, B., Roy, C.C. and Dommergues, J.P. (1999) Paediatric Castleman Disease: Report of Seven Cases and Review of the Literature. European Journal of Pe-diatrics, 158, 631-637.
https://doi.org/10.1007/s004310051166
|
[5]
|
Haap, M., Wiefels, J., Horger, M., et al. (2018) Clinical, Laboratory and Imaging Findings in Castleman’s Disease—The Subtype Decides. Blood Reviews, 32, 225-234. https://doi.org/10.1016/j.blre.2017.11.005
|
[6]
|
中华医学会血液学分会淋巴细胞疾病学组, 中国抗癌协会血液肿瘤专业委员会, 中国Castleman病协作组. 中国Castleman病诊断与治疗专家共识(2021年版) [J]. 中华血液学杂志, 2021, 42(7): 529-534.
|
[7]
|
Borocco, C., Ballot-Schmit, C., Ackermann, O., et al. (2020) The French Paediatric Cohort of Castleman Disease: A Retrospective Report of 23 Patients. Orphanet Journal of Rare Diseases, 15, Article No. 95.
https://doi.org/10.1186/s13023-020-1345-5
|
[8]
|
Sopfe, J., Endres, A., Campbell, K., et al. (2019) Castleman Dis-ease in Pediatrics: Insights on Presentation, Treatment, and Outcomes from a Two-Site Retrospective Cohort Study. Pe-diatric Blood & Cancer, 66, e27613.
https://doi.org/10.1002/pbc.27613
|
[9]
|
Chang, K., Wang, Y., Hung, L., et al. (2014) Monoclonality and Cytoge-netic Abnormalities in Hyaline Vascular Castleman Disease. Modern Pathology, 27, 823-831. https://doi.org/10.1038/modpathol.2013.202
|
[10]
|
Wu, D., Lim, M.S. and Jaffe, E.S. (2018) Pathology of Cas-tleman Disease. Hematology/Oncology Clinics of North America, 32, 37-52. https://doi.org/10.1016/j.hoc.2017.09.004
|
[11]
|
González García, A., Fernández-Martín, J. and Robles Marhuenda, Á. (2023) Idiopathic Multicentric Castleman Disease and Associated Autoimmune and Autoinflammatory Conditions: Practical Guidance for Diagnosis. Rheumatology, 62, 1426-1435. https://doi.org/10.1093/rheumatology/keac481
|
[12]
|
Fajgenbaum, D.C., Van Rhee, F. and Nabel, C.S. (2014) HHV-8-Negative, Idiopathic Multicentric Castleman Disease: Novel Insights into Biology, Pathogenesis, and Therapy. Blood, 19, 2924-2933.
https://doi.org/10.1182/blood-2013-12-545087
|
[13]
|
Fajgenbaum, D.C. (2018) Novel Insights and Therapeutic Ap-proaches in Idiopathic Multicentric Castleman Disease. Blood, 132, 2323-2330. https://doi.org/10.1182/blood-2018-05-848671
|
[14]
|
Leroy, S., Moshous, D., Cassar, O., et al. (2012) Multicentric Castleman Disease in an HHV-8-Infected Child Born to Consanguineous Parents. Pediatrics, 1, e199-e203. https://doi.org/10.1542/peds.2010-2739
|
[15]
|
Farruggia, P., Trizzino, A., Scibetta, N., et al. (2011) Castleman’s Disease in Childhood: Report of Three Cases and Review of the Literature. Italian Journal of Pediatrics, 37, Article No. 50. https://doi.org/10.1186/1824-7288-37-50
|
[16]
|
Kachur, E., Ang, L.C. and Megyesi, J.F. (2002) Castleman’s Disease and Spinal Cord Compression: Case Report. Neurosurgery, 50, 399-403. https://doi.org/10.1227/00006123-200202000-00031
|
[17]
|
Fajgenbaum, D.C., Uldrick, T.S., Bagg, A., et al. (2017) International, Evidence-Based Consensus Diagnostic Criteria for HHV-8-Negative/Idiopathic Multicentric Castleman Disease. Blood, 129, 1646-1657.
https://doi.org/10.1182/blood-2016-10-746933
|
[18]
|
Van Rhee, F., Oksenhendler, E., Srkalovic, G., et al. (2020) International Evidence-Based Consensus Diagnostic and Treatment Guidelines for Unicentric Castleman Disease. Blood Advances, 4, 6039-6050.
https://doi.org/10.1182/bloodadvances.2020003334
|
[19]
|
Zhang, M., Jia, M., Chen, J., et al. (2021) UCD with MCD-Like Inflammatory State: Surgical Excision Is Highly Effective. Blood Advances, 5, 122-128. https://doi.org/10.1182/bloodadvances.2020003607
|
[20]
|
Talat, N., Belgaumkar, A.P. and Schulte, K. (2012) Sur-gery in Castleman’s Disease. Annals of Surgery, 255, 677-684.
https://doi.org/10.1097/SLA.0b013e318249dcdc
|
[21]
|
Mukherjee, S., Martin, R., Sande, B., et al. (2022) Epidemi-ology and Treatment Patterns of Idiopathic Multicentric Castleman Disease in the Era of IL-6-Directed Therapy. Blood Advances, 6, 359-367.
https://doi.org/10.1182/bloodadvances.2021004441
|
[22]
|
Van Rhee, F., Wong, R.S., Munshi, N., et al. (2014) Sil-tuximab for Multicentric Castleman’s Disease: A Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet On-cology, 15, 966-974.
https://doi.org/10.1016/S1470-2045(14)70319-5
|